Category: Insulin

Amylin Lilly Logo

Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...
0 Shares
JDRF New Logo

JDRF Announces $100,000 Challenge for Development of Glucose Responsive Insulin

The Juvenile Diabetes Research Foundation (JDRF) and InnoCentive, Inc., the pioneer in open innovation and crowdsourcing, announced a $100,000 Challenge calling for innovative ways to approach the discovery and development of a glucose-responsive insulin drug as a means to treat insulin-dependent diabetes. The Challenge is open to the public and can be found on the InnoCentive website...
0 Shares
mannkind-logo

Mannkind Confirms Studies using Afrezza Insulin Threapy

MannKind Corporation announced that it has confirmed with the U.S. Food and Drug Administration the design of two clinical studies that evaluate the efficacy and safety of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation inhaler...
0 Shares
Novo Nordisk Logo

Novo Nordisk New Prefilled Insulin Pen Receives EU Approval

The European Commission has approved Novo Nordisk's new prefilled insulin pen – FlexTouch for use in the EU. The approval is for NovoRapid® (insulin aspart) and Levemir® (insulin detemir) - both modern insulins currently delivered in FlexPen. FlexTouch, the latest prefilled delivery system from Novo Nordisk, offers a new insulin injection experience for users...
0 Shares
InsuLine - logo

First Part of Clinical Trials Completed For InsuLine Diabetes Patch

InsuLine Medical, an Israeli based company whose mission is to develop and market technologies for type 1 and type 2 diabetes, announced that it has completed a first stage clinical trial to examine the effectiveness of its InsuPatch for adults with type 1 diabetes...
0 Shares
mannkind-logo

Inhaled Insulin, Afrezza, Does Not Increase Cardiovascular Risk

Treating type 1 and type 2 diabetes with investigational ultra rapid acting mealtime insulin Afrezza (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events according to two new studies being presented at the American Diabetes Association's...
0 Shares
Lilly

Eli Lilly’s Updated Humalog(R) Label Receives FDA Approval

The U.S. Food and Drug Administration (FDA) approved Eli Lilly's supplemental new drug application (sNDA) for Humalog(R) (insulin lispro injection [rDNA origin]). Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days...
0 Shares
Novo Nordisk Logo

Levemir Better for Treating Young Children with Type 1 Diabetes Than Human Basal Insulin

New clinical trial data just published in Pediatric Diabetes shows that Levemir (insulin detemir), Novo Nordisk’s basal insulin analogue, is an equally efficacious treatment option for two to five year-old children with type 1 diabetes, compared with human basal insulin, but is associated with lower hypoglycemic risk. Children with type 1 diabetes who are aged under six years...
0 Shares
biodel logo

Biodel to Accelerate Development of Ultra-Rapid-Acting Insulins

Biodel Inc. has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed...
0 Shares